William Beliveau, MD
Internal Medicine · Johnson, RINPI 1578588067
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (52.0%), ownership interests and food and beverage — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Anika Therapeutics, Inc. at 51.3% of the total. Reporting peaked in 2024 at $459,273 and has fallen 99.9% since, to $272 in 2025. Among internal medicine clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 243 payments — averaging $3915.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Anika Therapeutics, Inc.$488K
- Zimmer Biomet$459K
- AstraZeneca$1K
- GSK$528
- Mallinckrodt Hospital Products Inc.$384
- Nestle Healthcare Nutrition Inc.$328
- plus $2K from 30 others
Across 4 payments — averaging $2690.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$11K
What the payments were for
- Food & beverage$4,4140%
- Education$2170%
- Ownership interest$451,63547%
- Other$495,13352%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Anika Therapeutics, Inc. | 4 | $488,255 |
| Zimmer Biomet | 1 | $458,513 |
| AstraZeneca | 86 | $1,496 |
| GSK | 32 | $528 |
| Mallinckrodt Hospital Products Inc. | 15 | $384 |
| Nestle Healthcare Nutrition Inc. | 15 | $328 |
| Boehringer Ingelheim | 15 | $313 |
| Mylan Specialty L.p. | 6 | $121 |
| AbbVie | 5 | $112 |
| Regeneron Healthcare Solutions, Inc. | 5 | $102 |
| Johnson & Johnson | 4 | $96 |
| Insmed, Inc. | 4 | $95 |
| Sunovion Pharmaceuticals Inc. | 6 | $95 |
| Resmed Corp | 1 | $86 |
| Novartis | 4 | $77 |
| Amgen | 4 | $76 |
| ANI Pharmaceuticals, Inc. | 3 | $72 |
| E.r. Squibb & Sons, L.L.C. | 4 | $71 |
| Verona Pharma, Inc. | 3 | $65 |
| Vanda Pharmaceuticals Inc. | 2 | $59 |
| Actelion Pharmaceuticals US, Inc. | 2 | $56 |
| Amarin Pharma, Inc. | 3 | $51 |
| Biogen | 2 | $38 |
| Novo Nordisk | 2 | $35 |
| Merck | 2 | $32 |
| Antares Pharma, Inc. | 2 | $31 |
| Genentech USA, Inc. | 2 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Sanofi | 1 | $24 |
| Baxter Healthcare | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Eisai Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Grifols USA, LLC | 1 | $19 |
| Pfizer | 1 | $17 |
| Biomerieux Inc | 1 | $15 |
How this compares
$951,399 in reported general payments places this provider in the 95th percentile of 808 internal medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 13 | $564,702 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 311 | $219,005 |
| Breo ElliptaFluticasone/Vilanterol | 139 | $69,616 |
| Dupixent PenDupilumab | 11 | $48,388 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 58 | $37,852 |
| Wixela InhubFluticasone Propion/Salmeterol | 266 | $29,327 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 47 | $14,415 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 63 | $9,273 |
| EliquisApixaban | 20 | $6,419 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 136 | $3,764 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $3,255 |
| Ventolin HfaAlbuterol Sulfate | 58 | $2,769 |
| Montelukast Sodium | 173 | $2,531 |
| Prednisone | 157 | $1,022 |
| Fluticasone Propionate | 37 | $809 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $384 | $564,70213 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $528 | $288,621450 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,496 | $41,10770 claims |
| PfizerEliquis | $17 | $6,41920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 808 internal medicine providers in Rhode Island.
Other internal medicine in Johnson
- Katarzyna Gilek-SeibertProvidence$131K
- Randall InghamProvidence$100K
- Frank D'alessandroLincoln$93K
- Gregory AllenCranston$38K
- Richard RuggieriProvidence$30K
- Gerry OvideProvidence$29K
- Todd ViccioneEast Greenwich$22K
- Brian McCauleyProvidence$20K
- Daniel HochbergerRumford$20K
- Michael SteinRiverside$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.